Zacks Investment Research Downgrades Adamas Pharmaceuticals (ADMS) to Hold

Share on StockTwits

Adamas Pharmaceuticals (NASDAQ:ADMS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Wednesday, Zacks.com reports.

According to Zacks, “Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company’s portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. “

Other research analysts also recently issued research reports about the company. Piper Jaffray Companies set a $23.00 price target on Adamas Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, March 5th. HC Wainwright set a $40.00 target price on shares of Adamas Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, March 5th. Northland Securities restated a “buy” rating and set a $28.00 target price on shares of Adamas Pharmaceuticals in a research report on Tuesday, March 5th. BidaskClub upgraded shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, February 25th. Finally, ValuEngine upgraded shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, April 1st. Two research analysts have rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the stock. Adamas Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $20.28.

NASDAQ:ADMS traded up $0.20 during trading hours on Wednesday, hitting $5.69. 16,807 shares of the stock were exchanged, compared to its average volume of 300,079. Adamas Pharmaceuticals has a twelve month low of $5.36 and a twelve month high of $32.90. The company has a debt-to-equity ratio of 2.00, a quick ratio of 6.86 and a current ratio of 7.03. The company has a market cap of $150.59 million, a price-to-earnings ratio of -1.17 and a beta of 1.35.

Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its quarterly earnings results on Thursday, May 9th. The specialty pharmaceutical company reported ($1.08) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.13) by $0.05. The company had revenue of $11.67 million for the quarter, compared to the consensus estimate of $12.78 million. Adamas Pharmaceuticals had a negative return on equity of 122.40% and a negative net margin of 291.22%. On average, equities analysts predict that Adamas Pharmaceuticals will post -3.99 EPS for the current fiscal year.

In other Adamas Pharmaceuticals news, CEO Gregory T. Went sold 6,319 shares of Adamas Pharmaceuticals stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $7.99, for a total transaction of $50,488.81. Following the transaction, the chief executive officer now owns 176,291 shares of the company’s stock, valued at $1,408,565.09. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 8,361 shares of company stock worth $66,816 in the last ninety days. Insiders own 24.90% of the company’s stock.

A number of large investors have recently modified their holdings of ADMS. Jefferies Group LLC acquired a new stake in Adamas Pharmaceuticals in the 1st quarter valued at $107,000. Healthcare Value Capital LLC acquired a new stake in Adamas Pharmaceuticals in the 1st quarter valued at $711,000. Granite Investment Partners LLC acquired a new stake in Adamas Pharmaceuticals in the 1st quarter valued at $304,000. State of Wisconsin Investment Board grew its stake in Adamas Pharmaceuticals by 30.0% in the 1st quarter. State of Wisconsin Investment Board now owns 29,500 shares of the specialty pharmaceutical company’s stock valued at $210,000 after acquiring an additional 6,800 shares during the period. Finally, Swiss National Bank grew its stake in Adamas Pharmaceuticals by 6.7% in the 1st quarter. Swiss National Bank now owns 39,900 shares of the specialty pharmaceutical company’s stock valued at $284,000 after acquiring an additional 2,500 shares during the period. 88.03% of the stock is currently owned by institutional investors and hedge funds.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

Read More: How is Preferred Stock Different from Common Stock?

Get a free copy of the Zacks research report on Adamas Pharmaceuticals (ADMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Kite Realty Group Trust  Downgraded by ValuEngine to “Strong Sell”
Kite Realty Group Trust Downgraded by ValuEngine to “Strong Sell”
Target  Upgraded at Citigroup
Target Upgraded at Citigroup
Synlogic  Downgraded to “Sell” at Citigroup
Synlogic Downgraded to “Sell” at Citigroup
Trevi Therapeutics  Stock Rating Lowered by Zacks Investment Research
Trevi Therapeutics Stock Rating Lowered by Zacks Investment Research
B. Riley Analysts Give Urban Outfitters  a $23.00 Price Target
B. Riley Analysts Give Urban Outfitters a $23.00 Price Target
Loop Capital Boosts Home Depot  Price Target to $200.00
Loop Capital Boosts Home Depot Price Target to $200.00


 
© 2006-2019 Zolmax.